Northerner
Admin (Retired)
- Relationship to Diabetes
- Type 1
A medi tech business that is pioneering new developments in diabetes care technology has revealed its latest groundbreaking advance - an artificial pancreas.
CellNovo is partnering with US technology company TypeZero, who will use CellNovo's digitally-connected insulin patch pump alongside its own software in the artificial pancreas.
The artificial pancreas is designed to automatically monitor and regulate blood-sugar levels in people with Type 1 diabetes through the delivery of insulin.
Cellnovo is a multi-national company which is headquartered in France but has a major facility in Swansea's SA1 district, which it expanded last year with the renting of a second suite of offices. It recently raised £23m on Euronext exchange in Paris.
http://www.walesonline.co.uk/business/business-news/latest-advance-diabetes-care-medi-10846136
CellNovo is partnering with US technology company TypeZero, who will use CellNovo's digitally-connected insulin patch pump alongside its own software in the artificial pancreas.
The artificial pancreas is designed to automatically monitor and regulate blood-sugar levels in people with Type 1 diabetes through the delivery of insulin.
Cellnovo is a multi-national company which is headquartered in France but has a major facility in Swansea's SA1 district, which it expanded last year with the renting of a second suite of offices. It recently raised £23m on Euronext exchange in Paris.
http://www.walesonline.co.uk/business/business-news/latest-advance-diabetes-care-medi-10846136